Skip to content

Clinical trial to evaluate the efficacy of Chandrakala gutika and Mamajjaka Ghanavati in the management of madhumeha with special reference to Diabetes Mellitus type II.

Randomised comparative clinical trial to evaluate the efficacy of Chandrakala gutika and Mamajjaka Ghanavati in the management of madhumeha with special reference to Diabetes Mellitus type II - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084679
Enrollment
60
Registered
2025-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

National institute of ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient aged between 30 to 65 years 2. Patient having symptoms of Madhumeha 3. Patient with diagnosed cases of DM-II 4. Patient with FBS in range of 126mg/dl to 250mg/dl and PPBS in range of 200mg/dl to 350 mg/dl or both and HbA1c less than 10% 5. Patient consuming oral-hypoglycemic agents for a duration more than 1 year and having poor glycemic control 6. Patient with chronicity less than 5 years 7. Patient with willingness to participate in the study and provide informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Patient with type 1 diabetes 3. Patient with FBS more than 250mg/dl PPBS more than 350 mg/dl 4. Patients with Madhumeha upadrava or asadhya laxana 5. Patients with DM 2 on insulin therapy and Drug induced diabetes mellitus 6. Patients with hepatic impairment. 7. Uncontrolled hypertension

Design outcomes

Primary

MeasureTime frame
The primary outcome of the study will be the change in FBS/PPBS levels from baseline to the end of the treatment period.Timepoint: Baseline to the end of the treatment period.

Secondary

MeasureTime frame
Secondary outcomes will include changes subjective parameters, HbA1c, liver function tests, renal function tests, and incidence of adverse eventsTimepoint: Baseline, 45th day ,end of the treatment period. HbA1c-Baseline to the end of the treatment period.

Countries

India

Contacts

Public ContactDr Ajay Kumar Sahu Sir

National Institute of Ayurveda, Deemed to be university, Jaipur

drajaysahu@gmail.com9950708106

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026